361 Abstracts terns of prescription drugs were analyzed using SAS statistical software. RESULTS: A total of 3120 and 2791 patients with TC were identified in 2000 and 2001 respectively. The overall trends in 2000 were similar to those of 2001. In 2001, TC patients visited their physician office 1.3 times per year: 79% visited once a year, 15%-twice, 6%-more than twice. Three percentages of the patients continued to visit their physician office in the second year. Seventy-nine percent of the patients used at least 1 pre- scription for TC treatment, and 73% used an antifungal oral and/or topical agent. TC patients used an oral antifungal for 25 days on average. About 25% of the patients used an oral anti- fungal as monotherapy, the most common therapy. Among oral antifungals, griseofulvin was the most frequently used medica- tion (41%), followed by terbinafine (9%). Among newly diag- nosed patients, 73% used prescription drugs in the first year and 23% in the following year. CONCLUSIONS: TC patients used medical services and prescription drugs substantially in the year of diagnosis and many of these patients continuously used pre- scription drugs due to relapse of the symptoms in the following year. More effective therapy for TC could reduce the need for subsequent therapy. PIN34 THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER RESPIRATORY TRACT INFECTIONS IN A STATE MEDICAID POPULATION Coffi ndaff er JW 1 , Smith MJ 2 1 West Virginia University School of Pharmacy, Morgantown,WV, USA; 2 West Virginia University, Morgantown,WV, USA There is a growing concern in the United States regarding antibi- otic resistance due to inappropriate prescribing of antibiotics. OBJECTIVES: Report the patterns of oral antibiotics filled fol- lowing a medical visit for upper respiratory infection (URI) in a state Medicaid population. METHODS: The study sample included Medicaid recipients who had an outpatient or emer- gency department (ED) visit in 2002 for an acute URI. Outpa- tient and ED claims with a primary ICD-9-CM diagnosis code for acute nasopharyngitis, acute pharyngitis, acute URI, acute bronchitis, or influenza were extracted. Prescription claims for antibiotics filled within five days following a URI-related medical visit also were extracted. RESULTS: A total of 21,163 recipients were included in the study. Over 71% of the recipients were female, and nearly 95% were white. Recipients between 21 to 44 years of age accounted for more than half of the study group. Nearly half of all recipients made only one visit for URI through- out the year, and over 28% made 3 or more visits. Oral antibi- otics accounted for roughly 10% of the total prescriptions filled within 5 days following an acute URI-related medical visit. These antibiotics were for penicillins (41%), cephalosporins (15%), macrolides (11%), and others including quinolones, tetracy- clines, sulfonamides and trimethoprim (33%). CONCLUSION: One out of every ten prescriptions filled following an acute URI-related medical visit among recipients of Medicaid was for an oral antibiotic. Many upper respiratory tract infections are viral in nature, in which oral antibiotic treatment may be inappropriate. MEN’S HEALTH MEN’S HEALTH—Clinical Outcomes Studies PSD1 A SELF-ADMINISTERED SCREENER FOR MALE ERECTILE DISFUNCTION:THE SPANISH VERSION OF THE LIFE- SATISFACTION CHECK LIST “LISAT 8” Rejas J 1 , Gil A 2 , Martínez EM 3 , Díaz E 4 , San Isidro C 5 , Carrasco P 2 1 Health Outcomes Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain; 2 Rey Juan Carlos University, Alcorcón, Madrid, Spain; 3 Pfizer Medical Unit, Alcobendas, Madrid, Spain; 4 Primary Care Health Center Mendiguchía Garriche, Leganés, Madrid, Spain; 5 Health Center, Inocencio Jiménez, Zaragoza, Spain OBJECTIVE: To assess the validity and reliability of the self- administered Spanish version of the LISAT 8 as a screening tool for male ED in primary care settings. METHODS: A total of 653 subjects (537 ED and 116 nonED), >18 years, who reported attempting sexual activity and managed at Primary Care level, were extracted from a study designed to perform the cultural adaptation and validation into Spanish of the LISAT 8. Multi- variate logistic regression was applied to detect items or scale domains capable to be predictors of ED, and the ROC curves analysis to determine optimal cutoff score showing the best clini- metric indicators for sensitivity, specificity and positive and neg- ative predictive values to distinguish between ED and non ED subjects. Positive and negative likelihood ratios, area under the curve of the optimal cutoff score and kappa coefficient of agree- ment were also calculated. RESULTS: Items 2 and 8 of the check list (satisfaction with sexual life and satisfaction with partner relationship) which forms the affective domain of the instrument, were found to be predictors for ED. Mean (+standard deviation) for affective domain was significantly higher in nonED than in ED subjects; 9.2 + 2.1 pts versus 5.6 + 1.8 pts, p < 0.0001. This domain showed moderate, but statistically significant, correla- tion coefficients with IIEF and with each of its 5 domains (coef- ficients ranged between 0.44 and 0.69). ROC curves analysis showed an optimal cutoff score for ED of <8 pts; area under the curve = 0.892, p < 0.0001; sensitivity, 0.87; specificity, 0.84; pos- itive predictive value, 0.96; negative predictive value, 0.58; and kappa agreement coefficient = 0.602, p < 0.0001. CONCLU- SION: The domain satisfaction with affective life (items 2 and 3) of the Spanish version of the LISAT 8 showed adequate clini- metric properties of validity and reliability as a screening tool for male erectile dysfunction in Primary Care level. PSD2 ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD) IN EUROPE:A PRELIMINARY INVESTIGATION Williams VSL 1 ,F ehnel SE 1 , Hogue SL 2 1 RTI-Health Solutions, Research Triangle Park, NC, USA; 2 GlaxoSmithKline, RTP , NC, USA OBJECTIVE: Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitor (SSRI) antidepressants. Although widely acknowledged by US patients and physicians, this side effect is not as readily recognized in Europe. The goal of this study was to obtain preliminary estimates regarding the prevalence and impact of ADSD in two European countries. METHODS: This cross-sectional survey involved a total of 502 adults in France and the UK. All participants were taking an SSRI that had been newly prescribed within the previous three months. Information was gathered about patients’ current depression treatment, other medications and conditions known to impair sexual functioning, recent changes in sexual function- ing, and the impact of any such changes. The Medical Outcomes